{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:32:13Z","timestamp":1792467133397,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.cardfail.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T08:51:41Z","timestamp":1368521501000},"page":"390-397","source":"Crossref","is-referenced-by-count":135,"title":["Clinical Course of Patients With Hyponatremia and\u00a0Decompensated Systolic Heart Failure and the Effect of\u00a0Vasopressin Receptor Antagonism With Tolvaptan"],"prefix":"10.1016","volume":"19","author":[{"given":"Paul J.","family":"Hauptman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Grinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin A.","family":"Konstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Kostic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Udelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2013.04.001_bib1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2013.04.001_bib2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"Klein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2013.04.001_bib3","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2013.04.001_bib4","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2013.04.001_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2013.04.001_bib6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2013.04.001_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9343(96)00274-4","article-title":"Epidemiology, pathophysiology, and management of hyponatremic encephalopathy","volume":"102","author":"Fraser","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2013.04.001_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000441-200001000-00002","article-title":"Diuretic complications","volume":"319","author":"Greenberg","year":"2000","journal-title":"A J Med Sci"},{"key":"10.1016\/j.cardfail.2013.04.001_bib9","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2\u2013receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2013.04.001_bib10","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2013.04.001_bib11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/ki.2011.78","article-title":"Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet","volume":"80","author":"Gross","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.cardfail.2013.04.001_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/clc.20822","article-title":"Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options","volume":"33","author":"Jao","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2013.04.001_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0735-1097(87)80278-4","article-title":"Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition\u00a0in severe chronic heart failure","volume":"10","author":"Packer","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2013.04.001_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","article-title":"Impact of hospital-associated hyponatremia on selected outcomes","volume":"170","author":"Wald","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2013.04.001_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2013.04.001_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2013.04.001_bib17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2013.04.001_bib18","first-page":"351","article-title":"One the combination of independent two-sample tests of Wilcoxin","volume":"37","author":"van Elteren","year":"1960","journal-title":"Bull Int Stat Inst"},{"key":"10.1016\/j.cardfail.2013.04.001_bib19","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","article-title":"Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model","volume":"290","author":"Lee","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2013.04.001_bib20","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2013.04.001_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr","year":"2011","journal-title":"Am J Health-Sys Pharm"},{"key":"10.1016\/j.cardfail.2013.04.001_bib22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2013.04.001_bib23","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916413001000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916413001000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T01:54:38Z","timestamp":1539654878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916413001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1071916413001000"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2013.04.001","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}